stockrow
Friday 6 November 2026
Export QSI’s income statement to Excel — free account
Quantum-Si Incorporated
QSI Healthcare Medical Devices
Quantum-Si Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, down 20.3% from fiscal 2024.
- Revenue
- −61.6%
- EPS
- +41.2%
- Free cash flow
- +37.5%
Quarter to September 2026, against a year earlier
1.34
0.17
+14.53%
Follow QSI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 1 | 3 | 2 | 1 | +50.0% | 1 | 6 | 22 | +107.1% | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 45.10 | 52.32 | 47.33 | 34.94 | +47.3 pt | ||||||
| EBT | — | — | — | (36) | (37) | (95) | (132) | (96) | (101) | (101) | (85) | +18.9% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (8,868.76) | (3,301.21) | (4,157.68) | (6,738.81) | (4,157.7) pt | ||||||
| Net income | — | 0 | — | (36) | (37) | (95) | (132) | (96) | (101) | (101) | (85) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.01 | n/m | |||||
| Earnings | — | — | — | (6.95) | (6.84) | (1.19) | (0.95) | (0.68) | (0.71) | (0.51) | (0.39) | (35.3%) | ||||||
| Cash flow | — | — | — | (5.97) | (6.08) | (0.84) | (0.65) | (0.67) | (0.61) | (0.48) | (0.37) | (34.3%) | ||||||
| Capex | — | — | — | (0.24) | (0.09) | (0.07) | (0.08) | (0.04) | (0.03) | (0.01) | 0.00 | (38.8%) | ||||||
| Free cash flow | — | — | — | (6.21) | (6.17) | (0.91) | (0.73) | (0.70) | (0.65) | (0.49) | (0.37) | (34.5%) | ||||||
| Book value | — | — | — | 0.00 | (29.82) | 5.99 | 2.58 | 1.92 | 1.50 | 1.11 | 0.73 | n/m | ||||||
| Shares, m | — | — | — | 5 | 5 | 80 | 139 | 141 | 143 | 198 | 213 | +83.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 265.10 | 126.43 | 89.30 | 202.54 | 160.3 | ||||||
| P/B | — | — | — | — | — | — | — | 1.06 | 1.79 | 0.99 | 1.60 | 1.3 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 26.90 | 57.89 | 22.43 | 120.71 | 35.7 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (0.29) | (1.92) | (0.56) | (1.88) | (0.9) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (31) | (33) | (67) | (91) | (94) | (88) | (95) | (81) | +20.7% | |||||
| Capex | — | — | — | (1) | 0 | (6) | (11) | (5) | (5) | (3) | 0 | +12.5% | ||||||
| Free cash flow | — | — | — | (32) | (33) | (73) | (101) | (99) | (92) | (97) | (81) | +20.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 35 | 466 | 342 | 255 | 200 | 153 | 101 | +34.2% | |||||
| Net debt | — | — | — | — | (35) | (471) | (351) | (258) | (210) | (163) | (104) | +35.9% | ||||||
| Shareholders’ equity | — | — | — | — | (160) | 477 | 359 | 272 | 215 | 220 | 160 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (180.40) | (34.93) | (29.61) | (27.83) | (36.99) | (41.07) | (39.32) | (41.1) pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (1,057.02) | (1,046.38) | (500.48) | (1,166.58) | (126.60) | (104.20) | (126.6) pt | ||||||
| ROE | — | — | — | 0.00 | (23.08) | (59.87) | (31.69) | (30.45) | (41.48) | (46.52) | (43.06) | (46.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 2 | 153 | 196 | 159 | 143 | 145 | — | +135.5% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
Quantum-Si Incorporated vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CV CapsoVision, Inc. | $329.9M | — (loss-making) | — (loss-making) | +9.89% (above 0%: growing) | n/m | −84.44% (below 0%: shrinking) | 51.36% | (208.07%) | Compare |
| CLPT ClearPoint Neuro, Inc. | $278.6M | — (loss-making) | — (loss-making) | +36.27% (above 0%: growing) | n/m | −58.10% (below 0%: shrinking) | 58.46% | (52.44%) | Compare |
| TMCI Treace Medical Concepts, Inc. | $271.9M | — (loss-making) | — (loss-making) | −4.24% (below 0%: shrinking) | n/m | +11.74% (above 0%: growing) | 78.47% | (32.96%) | Compare |
| INFU InfuSystems Holdings, Inc. | $270.1M | 32.0× | 33.0× | +2.59% (above 0%: growing) | +33.33% (above 0%: growing) | −66.54% (below 0%: shrinking) | 57.98% | 11.24% | Compare |
| QSI Quantum-Si Incorporated | $256.1M | — (loss-making) | — (loss-making) | −61.59% (below 0%: shrinking) | n/m | +37.48% (above 0%: growing) | 34.91% | (11,215.09%) | |
| PROF Profound Medical | $251.3M | — (loss-making) | — (loss-making) | +85.86% (above 0%: growing) | n/m | +47.93% (above 0%: growing) | 78.13% | (79.56%) | Compare |
| LAB Standard BioTools Inc. | $245.7M | 1.8× | — (loss-making) | −0.85% (below 0%: shrinking) | n/m | +73.32% (above 0%: growing) | 55.86% | (101.98%) | Compare |
| ELMD Electromed, Inc. | $221.8M | 19.4× | 18.6× | +11.64% (above 0%: growing) | +57.69% (above 0%: growing) | −25.15% (below 0%: shrinking) | 78.71% | 19.70% | Compare |
| TLSI TriSalus Life Sciences, Inc. | $217.4M | — (loss-making) | — (loss-making) | +1.73% (above 0%: growing) | n/m | −41.29% (below 0%: shrinking) | 86.78% | (86.03%) | Compare |
| Median of peers | $260.7M | 19.4× | — | +6.24% | — | −33.22% | 68.30% | (66.00%) |
Pay and ownership Proxy statement filed 1 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 3.18m | (2.91m) | 60.11 |
| 2024 | 4.44m | 8.72m | 147.54 |
| 2023 | 1.05m | 1.92m | 109.84 |
Ownership
Directors and executive officers, together
70.65% of the votes
Jonathan M. Rothberg, Ph.D.
69.33% of the votes
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement